SGLT2 Inhibitors Reduce Gout Flares and CV Events. A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/laOh4CsZ8Z https://t.co/6oas9AWc8j